Related Experiment Video
Updated: Feb 2, 2026

Genetic Variant Detection in the CALR gene using High Resolution Melting Analysis
Published on: August 26, 2020
CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis
Marty Richardson1, Jamie Kirkham2, Kerry Dwan3
1Department of Biostatistics, University of Liverpool, Liverpool, L69 3GB, UK. mhr@liverpool.ac.uk.
Background:
Treatment with anti-tuberculosis drugs may cause patients to experience serious adverse effects. Genetic factors, such as polymorphisms of CYP genes, may increase the likelihood of a patient experiencing such adverse drug reactions. In this systematic review and meta-analysis, we synthesised evidence for associations between CYP genetic variants and anti-tuberculosis drug-related toxicity outcomes.
Methods:
We searched MEDLINE, PubMed, EMBASE, BIOSIS and Web of Science to identify relevant studies. We performed meta-analyses to obtain an effect estimate for each genetic variant on each outcome, and stratified all analyses by country. We qualitatively assessed the methodological quality of the included studies.
Results:
We included data from 28 distinct cohorts of patients in the review. We identified many areas of concern with regard to the quality of included studies. Patients with homozygous mutant-type or heterozygous genotype at the CYP2E1 RsaI polymorphism were significantly less likely to experience hepatotoxicity than patients with homozygous wild-type genotype (odds ratio [OR] = 0.75, 95% confidence interval [CI] 0.56-1.00; p = 0.047, I2 = 58.2%). No significant differences were observed for the CYP2E1 DraI and PstI polymorphisms. For the 96-bp deletion-insertion single-nucleotide polymorphism (SNP) of the CYP2E1 gene, homozygous mutant-type significantly increased hepatotoxicity risk compared with homozygous wild-type (OR = 8.20, 95% CI 1.38-48.68, I2 = 0%); no significant difference was observed for heterozygous genotype compared with homozygous wild-type (OR = 0.77, 95% CI 0.19-3.21, I2 = 0%).
Conclusions:
Generally, we identified that coverage of the association between SNPs of CYP genes and anti-tuberculosis drug-related toxicity outcomes is incomplete. We observed significant associations between the RsaI and 96-bp deletion-insertion SNPs of the CYP2E1 gene and anti-tuberculosis drug-related hepatotoxicity. We were unable to comment on the impact of ethnicity on the investigated associations, as information on participants' ethnicity was sparsely reported in the included studies.
Systematic Review Registration:
PROSPERO registration number: CRD42017068448.
Insights
This study found that certain CYP2E1 gene variations are linked to anti-tuberculosis drug-induced liver damage. Understanding these genetic factors may help predict and prevent adverse drug reactions in patients undergoing tuberculosis treatment.
Area of Science:
- Pharmacogenomics
- Tuberculosis treatment
- Drug toxicity
Background:
- Anti-tuberculosis drugs can cause severe adverse effects.
- Genetic factors, including CYP gene polymorphisms, may influence drug toxicity.
- Understanding these associations is crucial for patient safety.
Purpose of the Study:
- To systematically review and meta-analyze evidence on the association between CYP genetic variants and anti-tuberculosis drug toxicity.
- To synthesize findings from multiple studies to provide a comprehensive overview.
Main Methods:
- Conducted a systematic search of major scientific databases (MEDLINE, PubMed, EMBASE, BIOSIS, Web of Science).
- Performed meta-analyses to estimate the effect of each genetic variant on toxicity outcomes.
- Stratified analyses by country and qualitatively assessed study quality.
Main Results:
- Included data from 28 distinct patient cohorts.
- Found significant associations between CYP2E1 RsaI polymorphism and reduced hepatotoxicity risk (OR=0.75).
- Identified a significantly increased hepatotoxicity risk with the CYP2E1 96-bp deletion-insertion polymorphism (OR=8.20).
Conclusions:
- Coverage of the association between CYP gene SNPs and anti-tuberculosis drug toxicity is incomplete.
- Specific CYP2E1 gene polymorphisms (RsaI, 96-bp deletion-insertion) are significantly associated with anti-tuberculosis drug-related hepatotoxicity.
- Limited ethnicity data prevented analysis of ethnic impact on these associations.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Histone Variants at the Centromere
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups